In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

Strong membrane staining in the normal epithelial ... This principle is indeed used in the algorithms for HER2 testing proposed by the ASCO/CAP guidelines. The preanalytical variants can similarly ...

Relationship between PD-L1 expression and the number of biopsy specimens in advanced gastric cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

Predicting mortality in upper gastrointestinal tract cancer using long short-term memory neural networks. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

is presenting clinical data from a completed Phase 1 trial evaluating a novel autologous HER2-targeted CAR-T therapy. The data presented today at the ASCO Gastrointestinal Cancers Symposium ...

a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological malignancies, is presenting clinical data from a completed Phase 1 trial ...